[Intraarterial chemoembolization therapy for unresectable liver cancer using plachitin particles]

Area of Science:

• Oncology
• Interventional Radiology
• Materials Science

Background:

• Unresectable liver cancer presents significant treatment challenges.
• Arterial chemoembolization offers a localized drug delivery approach.
• Plachitin, a composite of chitin and cis-diamminedichloroplatinum (CDDP), was developed for this purpose.

Observation:

• Three patients with unresectable liver cancer (hepatocellular carcinoma, bile duct cystadenocarcinoma, and liver metastases) received Plachitin arterial chemoembolization.
• Tumor regression rates varied from 39% to 84.4% after one to three courses.
• Tumor markers such as alpha-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA) showed significant decreases.

Findings:

• Plachitin chemoembolization achieved objective tumor responses in 66.7% of the treated patients.
• Pharmacokinetic studies indicated low systemic platinum (Pt) levels, with transient elevations in urine Pt.
• Adverse effects were generally transient and manageable, including nausea, fever, and elevated liver enzymes, with no observed renal hypofunction.

Implications:

• Plachitin demonstrates potential as an effective and tolerable intra-arterial therapy for primary and secondary liver cancers.
• The localized delivery minimizes systemic toxicity, offering a potential advantage over conventional chemotherapy.
• Further investigation is warranted to establish Plachitin's role in liver cancer treatment protocols.